IBS C News and Research

RSS

Side effects may limit use of Prometheus's Lotronex for IBS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.

5 Apr 2010

Gastrointestinal tract disorders GERD and IBS interlinked

Gastroesophageal reflux disorder (GERD) and irritable bowel syndrome (IBS) are two very common disorders affecting the gastrointestinal tract. About 10% of the population experience daily discomfort from reflux of gastric contents into the esophagus. More than 10% of the population experience abdominal pain and disturbed bowel movement because of irritable bowel syndrome.

2 Apr 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

Renowned expert to present latest research on gut microbes at EICC

Trillions and trillions of bacteria live in the human gut. The thought of all these invisible inhabitants inside you might be yucky, but without them we would not be here at all. Which microbes reside in our gut? Are they harmful? Where do they come from? What do they actually do deep in our bowels? Do pre- or pro- biotics affect them?

25 Mar 2010

Colorectal cancer survivor shares her experience

For Hempstead resident Lynette Love, mother of four and grandmother of five, surviving colorectal cancer took courage, diligence and faith. Now a 3-year survivor, Love is giving the love back to the community through her participation in the Sprint for Colorectal Oncology Prevention and Education (SCOPE) run.

25 Mar 2010

Working rotating shifts may increase risk of developing IBS and abdominal pain

Nurses participating in shift work, especially those working rotating shifts, face a significantly increased risk of developing Irritable Bowel Syndrome (IBS) and abdominal pain compared to those working a standard day-time schedule, according to research published in the American Journal of Gastroenterology.

19 Mar 2010

Hypnotherapy and probiotics effective for reducing IBS symptoms

Hypnotherapy seems to be very effective for easing the distressing symptoms of irritable bowel syndrome (IBS), and in a goodly proportion of cases, clears up symptoms altogether, reveal experts during a wide ranging discussion of the condition in a Frontline Gastroenterology podcast.

18 Mar 2010

2010 European LDN Conference: LDN can be used as effective treatment for people with MS

People with MS (Multiple Sclerosis) and others suffering with a range of often debilitating inflammatory conditions such as Chronic Fatigue Syndrome and Fibromyalgia, will take heart from advances in treatment for their conditions, and will follow events at The 2nd European LDN Conference with interest.

10 Mar 2010

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.

10 Mar 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Tioga Pharmaceuticals, Inc. today announced the closing of an $18 million equity financing. Current investors Forward Ventures, New Leaf Venture Partners and BB Biotech Ventures were joined by new investor Genesys Capital Partners.

17 Feb 2010

Exagen Diagnostics, EndoChoice announce agreement for promoting diagnostic services to U.S. gastroenterologists

Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

17 Feb 2010

InfoSpi to acquire business and advanced technology of Integral Bioenergies Systems

InfoSpi Inc. (OTC Bulletin Board: ISPI) announced today an important development within the process of the negotiations to acquire the business and advanced technology of Integral Bioenergies Systems, SL (IBS). This firm has developed and protected a proprietary technology process that allows the treatment of biomass/sludge obtained at sewage treatment plants.

6 Feb 2010

New research may help adopt acupuncture as a treatment option for NHS patients

Important new research about the effects of acupuncture on the brain may provide an understanding of the complex mechanisms of acupuncture and could lead to a wider acceptability of the treatment.

4 Feb 2010

DNA variations in genes increase risk of developing PI-IBS

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton's citizens gave a team of researchers a unique opportunity to study the origin of this disorder.

28 Jan 2010

Alterations in intestinal microbiota may lie behind IBS aetiology

Irritable bowel syndrome (IBS) is a common gastrointestinal functional disorder that can greatly affect the patient's well being. Multiple interacting mechanisms, including alterations in the intestinal microbiota, are suspected to lie behind IBS aetiology.

18 Jan 2010

Findings suggest abuse is a risk factor for chronic headache

Researchers from the American Headache Society's Women's Issues Section Research Consortium found that incidence of childhood maltreatment, especially emotional abuse and neglect, are prevalent in migraine patients.

5 Jan 2010

St. John's wort not effective in treating IBS

A Mayo Clinic research study published in the January issue of the American Journal of Gastroenterology finds that St. John's wort is not an effective treatment for irritable bowel syndrome (IBS). While antidepressants are frequently used to treat IBS, to date, no study has examined the success of using the herbal supplement St. John's wort in treating IBS.

5 Jan 2010

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Salix Pharmaceuticals, Ltd. today reported that the Company held a pre-NDA meeting on December 8, 2009 with the FDA to discuss the Company’s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

10 Dec 2009

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA).

2 Dec 2009